Nanoscope Therapeutics Taps Gene Therapy Supply Chain Veteran Ahead…

Event summary

Nanoscope Therapeutics appoints Troy Short as Senior Vice President, Manufacturing and Supply Chain, effective October 14, 2026.
Short brings over 20 years of experience in gene therapy operations, including leading the global supply chain for Zolgensma® at AveXis.
Nanoscope's Biologics License Application (BLA) for MOGENRY is under FDA review, with a Japan New Drug Application (JNDA) also under PMDA review.
MOGENRY is a one-time intravitreal optogenetic gene therapy designed for inherited retinal dystrophies (IRDs).
Short's role focuses on strengthening manufacturing partnerships and building a resilient commercial supply chain for MOGENRY's potential launch.

The big picture

Nanoscope's appointment of Troy Short underscores the critical role of supply chain expertise in the gene therapy sector, particularly as companies prepare for commercial launches. The move comes as Nanoscope advances MOGENRY through regulatory reviews in the U.S. and Japan, highlighting the strategic importance of manufacturing and distribution capabilities in bringing complex therapies to market. The industry is increasingly focused on operational readiness to support the scaling of gene therapies, which require specialized handling and logistics.

What we're watching

Regulatory Approval Timing: The pace at which the FDA and PMDA review processes for MOGENRY will determine the commercialization timeline and market entry strategy.
Supply Chain Execution: Whether Troy Short can replicate his success in scaling gene therapy supply chains at Nanoscope, ensuring global distribution readiness for MOGENRY.
Market Penetration: How Nanoscope positions MOGENRY in a competitive landscape where most IRD patients currently lack approved treatment options.